Evaluaci´on

R

Abellan, R., Ventura, R., Pichini, S., Palmi, I., Bellver, M., Olive, R., Pacifici, R., Pascual, J.A., Zuccaro, P., Segura, J. (2007). Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse. Int J Sports Med, 28(1), 9-15.

Adamson, J.W., Vapnek, D. (1991). Recombinant human erythropoietin to improve athletic performance. N Eng J Med, 324, 698-699.

Baptista, S., Piloto, N., Reis, F., et al. (2008) Treadmill running and swimming imposes distinct cardiovascular physiological adaptations in the rat: focus on serotonergic and sympathetic nervous systems modulation. Acta Physiol Hung., 95, 235-251.

Bento, R., Damasceno, L., Neto, F. (2003). Eritropoietina recombinante humana no esporte:

uma revisão. Rev Bras Med Esporte, 9, 169-180.

Benzie, I.F.F, Strain, J.J. (1996). The Ferric Reducing Ability of Plasma (FRAP) as a Measure of ‘‘Antioxidant Power’’: The FRAP Assay. Anal Biochem, 239, 70-76.

Berglund, B., Birgegard, G., Hemmingsson, P. (1988). Serum erythropoietin in cross country skiers. Med. & Sci. in Sports Exercise, 20, 208-209.

Beullens, M., Delanghe, J.R., Bollen, M. (2006). False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood, 107(12), 4711-4713.

Bogoyevitch, M.A. (2004). An update on the cardiac effects of erythopoietin cardioprotetion by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res, 63: 208-216.

Cazzola, M. (2002). A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica, 85, 561-563.

Cruz, A. (2006). Resistência aeróbia e eritropoietina. Goiânia, 33, 553-572.

Delanghe, J.R., Bollen, M., Beullens, M. (2008). Testing for recombinant erythropoietin. Am J Hematol, 2008, 83(3), 237-241.

Diamanti-Kandarakis, E., Konstantinopoulos, P.A., Papailiou, J., Kandarakis, S.A., Andreopoulos, A., Sykiotis, G.P. (2005). Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med, 35(10), 831-840.

Elliott, S. (2008). Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br J Pharmacol, 154, 529-541.

Estepa, V., Ródenas, S., Martín, M.C. (2001). Optimización de un método para la determinación de la peroxidación lipídica en suero humano. Anal Real Acad Farm, 67, 1-17.

Fliser, D., Bahlmann, F.H., Haller, H. (2006). EPO: renoprotetion beyond anemia correction.

Pediatr Nephrol, 21, 1785-1789.

Gareau, R., Audran, M., Baynes, R.D., Flowers, C.H., Duvallet, A., Senécal, L., Brisson, G.R. (1996). Erythropoietin abuse in athletes. Nature, 380, 113.

Gauthier, J. (2001). Effets cardiovasculaires du dopage. Ann Cardiol Angeiol, 50293, 8.

Ghezzi, P., Brines, M. (2004). Erythropoietin as an antiapoptotic, tissue-protective cytokine.

Cell Death & Differentiation, 11, S37-S44.

Katavenin, P., Tungsanga, K., Eiam-Ong, S., Nagaku, M. (2007). Antioxidative effects of erythropoietin. Kidney Int, 72, S10-S15.

Lacombe, C., Mayeux, P. (2006). Biology of erythropoietin. Haematologica, 83, 724-732.

Lamon, S., Martin, L., Robinson, N., Saugy, M., Ceaurriz, J., Lasne, F. (2009). Effects of exercise on the isoelectric patterns of erythropoietin. Clin J Sport Med., 19(4), 311-315.

Lasne, F., de Ceaurriz, J. (2000). Recombinant human erythropoietin in urine. Nature, 405, 635.

Latini, R., Brines, M., Fiordaliso, F. (2008). Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev, 13, 415-423.

Lipsic. E., Schoemaker, R.G., van der Meer, P., Voors. A.A., van Veldhuisen, D.J., van Gilst, W.H. (2006). Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol, 48(11), 2161-2167.

Livak, K.J., Schmittgen, T.D. (2001). Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2- ΔΔCT. Method Methods, 25, 402–408.

Maiese, K., Chong, Z.Z., Hou, J., Shang, Y.C. (2008). Erythropoietin and oxidative stress.

Curr Neurovasc Res, 5, 125-142.

Manolis, A.S., Tzeism, S., Triantafyllou, K., Michaelidis, J., Pyrros, I., Sakellaris, N., Kranidis, A., Melita, H. (2005). Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets – Cardiovasc &

Haematol Dis, 5, 355-375.

Mastromarino, V., Volpe, M., Musumeci, M.B., Autore, C., Conti, E. (2011) Erythropoietin and the heart: facts and perspectives. Clin Sci (Lond), 120(2), 51-63.

Meilhac, O., Ramachandran, S., Chiang, K., et al. (2001). Role of arterial wall antioxidant defense in beneficial effects of exercise on atherosclerosis in mice. Arterioscler Thromb

& Vasc Biol, 21, 1681-1688.

Parsa, C.J., Matsumoto, A., Kim, J., Riel, R.U., Pascal, L.S., Walton, G.B., Thompson, R.B., Petrofski, J.A., Annex, B.H., Stamler, J.S., Koch, W.J. (2003). A novel protective effect of erythropoietin in the infracted heart. J, Clin, Investig, 112, 999-1007.

Pascual, J.A., Belalcazar, V., de Bolos, C., Gutiérrez, R., Llop, E., Segura, J. (2004).

Recombinant erythropoietin and analogues: a challenge for doping control. Ther Drug Monit, 26(2), 175-179.

Piloto, N., Teixeira, H.M., Teixeira-Lemos, E., Parada, B., Garrido, P., Sereno, J., Pinto, R., Carvalho, L., Costa, E., Belo, L., Santos-Silva, A., Teixeira, F., Reis, F. (2009).

Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic sports doping. Cardiovasc Toxicol, 9(4), 201-210.

Regidor, D.L., Kopple, J.D., Kovesdy, C.P., Kilpatrick, R.D., McAllister, C.J., Aronovitz, J., Greenland, S., Kalantar-Zadeh, K. (2006). Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.

J Am Soc Nephrol, 17, 1181-1191.

Reis, F., Rocha, L., Ponte, L., Alcobia, T., Almeida, L., Costa-Almeida, C., Teixeira, F.

(2005). Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sci, 77, 2514–2528.

Riksen, N.P., Hausenloy, D.J., Yellon, D.M. (2008). Erythropoietin: ready for prime-time cardioprotection. TiPS, 29, 258-267.

Robinson, N., Mangin, P., Saugy, M. (2003). Erythropoietin abuse in sports. Sysmex J Int, 13, 75-77.

Scheen, A.J., Pharma-clinics. (1998). Doping with erythropoietin or the misuse of therapeutic advances. Rev Med Liege, 53(8), 499-502.

Schwandt, H.J., Heyduck, B., Gunga, H.C., Röcker, L. (1991). Influence of prolonged physical exercise on the erythropoietin concentration in blood. Eur J Appl Physiol Occup Physiol, 63, 463-466.

Scott, J., Phillips, G.C. (2005). Erythropoietin in sports: a new look at an old problem. Curr Sports Med Rep, 4(4), 224-226.

Smith, S.A., Mitchell, J.H., Garry, M.G. (2006). The mammalian exercise pressor reflex in health and disease. Exp Physiol, 91, 89-102.

Stohlawetz, P.J., Dzirlo, L., Hergovich, N., Lackner, E., Mensik, C., Eichler, H.G., Kabrna, E., Geissler, K., Jilma, B. (2000). Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood, 95, 2983-2999.

Thein, L.A., Thein, J.M., Landry, G.L. (1995). Ergogenic aids. Phys Ther, 75, 426-439.

Torralbo, A., Herrerro, J.A., Portolé,s J., Fontanellas, A., Barrientos, A. (1995). Activation of the sympathetic nervous system in hemodialyzed patients treated with erythropoietin.

Nephron, 69, 350.

van der Putten, K., Braam, B., Jie, K.E., Gaillard, C.A. (2008). Mechanisms of Disease:

erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol, 4(1), 47-57.

Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., et al.

(2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol, 3(7), RESEARCH0034.

Voss, S., Lüdke, A., Romberg, S., Schänzer, E., Flenker, U., de Marees, M., Achtzehn, S., Mester, J., Schänzer, W. (2010). Effects of high intensity exercise on isoelectric profiles and SDS-PAGE mobility of erythropoietin. Int J Sports Med, 31(6), 367-371.

Wagner, KF, Katschinski DM, Hasegawa J, Schumacher D, Meller B, Gembruch U, Schramm U, Jelkmann W, Gassmann M, Fandrey J. (2001). Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97: 536-542.

Editors: João H. Bastos and Andreia C. Silva © 2012 Nova Science Publishers, Inc.

Chapter 5

A THLETIC H EART : T HE P OSSIBLE R OLE